558 related articles for article (PubMed ID: 24325405)
21. [Association of interleukin 28B polymorphisms with response to pegylatedinterferon plus ribavirin therapy for chronic hepatitis C].
Xu H; Guo LL; He LL; Chen Y; Liu K; Lei BJ; Lei XZ
Sichuan Da Xue Xue Bao Yi Xue Ban; 2012 Nov; 43(6):855-9. PubMed ID: 23387213
[TBL] [Abstract][Full Text] [Related]
22. Pegylated interferon plus ribavirin is suboptimal in IL28B CC carriers without rapid response.
Neukam K; Barreiro P; Rivero-Juárez A; Caruz A; Mira JA; Camacho A; Macías J; Rivero A; Soriano V; Pineda JA
J Infect; 2013 Jul; 67(1):59-64. PubMed ID: 23542783
[TBL] [Abstract][Full Text] [Related]
23. Interleukin 28B polymorphism predicts pegylated interferon plus ribavirin treatment outcome in chronic hepatitis C genotype 4.
De Nicola S; Aghemo A; Rumi MG; Galmozzi E; Valenti L; Soffredini R; De Francesco R; Prati GM; D'Ambrosio R; Cheroni C; Donato MF; Colombo M
Hepatology; 2012 Feb; 55(2):336-42. PubMed ID: 21932415
[TBL] [Abstract][Full Text] [Related]
24. Role of Interleukin 28B Polymorphisms in Response to Interferon Based Therapy for Hepatitis C Virus Clearance.
Asthana M; Sahu SK; Kumar A; Mohanty S; Chakrabarti S; Das P; Chattopadhya NR; Chatterjee K; Singh SP; Rajasubramaniam S; Choudhuri T
Curr Drug Metab; 2018; 19(3):215-223. PubMed ID: 29380700
[TBL] [Abstract][Full Text] [Related]
25. Early anemia and rapid virological response improve the predictive efficiency of IL28B-genotype for treatment outcome to antiviral combination therapy in patients infected with chronic HCV genotype 1.
Amanzada A; Schneider S; Moriconi F; Lindhorst A; Suermann T; van Thiel DH; Mihm S; Ramadori G
J Med Virol; 2012 Aug; 84(8):1208-16. PubMed ID: 22711348
[TBL] [Abstract][Full Text] [Related]
26. IFNL3 (IL28B) and IFNL4 polymorphisms are associated with treatment response in Thai patients infected with HCV genotype 1, but not with genotypes 3 and 6.
Akkarathamrongsin S; Thong VD; Payungporn S; Poovorawan K; Prapunwattana P; Poovorawan Y; Tangkijvanich P
J Med Virol; 2014 Sep; 86(9):1482-90. PubMed ID: 24782280
[TBL] [Abstract][Full Text] [Related]
27. Interleukin-28B single nucleotide polymorphism of donors and recipients can predict viral response to pegylated interferon/ribavirin therapy in patients with recurrent hepatitis C after living donor liver transplantation.
Kawaoka T; Takahashi S; Takaki S; Hiramatsu A; Waki K; Hiraga N; Miki D; Tsuge M; Imamura M; Kawakami Y; Aikata H; Ochi H; Onoe T; Tashiro H; Ohdan H; Chayama K
J Gastroenterol Hepatol; 2012 Sep; 27(9):1467-72. PubMed ID: 22432893
[TBL] [Abstract][Full Text] [Related]
28. Relevance of low viral load in haemodialysed patients with chronic hepatitis C virus infection.
Sperl J; Frankova S; Senkerikova R; Neroldova M; Hejda V; Volfova M; Merta D; Viklicky O; Spicak J; Jirsa M
World J Gastroenterol; 2015 May; 21(18):5496-504. PubMed ID: 25987772
[TBL] [Abstract][Full Text] [Related]
29. Genetic variant of IL28B rs12979860, as predictive marker of interferon-based therapy in Pakistani population.
Imran M; Manzoor S; Azam S; Resham S
APMIS; 2015 Apr; 123(4):342-9. PubMed ID: 25703417
[TBL] [Abstract][Full Text] [Related]
30. Host genomics and HCV treatment response.
Clark PJ; Thompson AJ
J Gastroenterol Hepatol; 2012 Feb; 27(2):212-22. PubMed ID: 21916985
[TBL] [Abstract][Full Text] [Related]
31. Association of IL28B variants with response to pegylated-interferon alpha plus ribavirin combination therapy reveals intersubgenotypic differences between genotypes 2a and 2b.
Sakamoto N; Nakagawa M; Tanaka Y; Sekine-Osajima Y; Ueyama M; Kurosaki M; Nishida N; Tamori A; Yuki NS; Itsui Y; Azuma S; Kakinuma S; Hige S; Itoh Y; Tanaka E; Hiasa Y; Izumi N; Tokunaga K; Mizokami M; Watanabe M;
J Med Virol; 2011 May; 83(5):871-8. PubMed ID: 21360545
[TBL] [Abstract][Full Text] [Related]
32. Influence of genes suppressing interferon effects in peripheral blood mononuclear cells during triple antiviral therapy for chronic hepatitis C.
Iijima S; Matsuura K; Watanabe T; Onomoto K; Fujita T; Ito K; Iio E; Miyaki T; Fujiwara K; Shinkai N; Kusakabe A; Endo M; Nojiri S; Joh T; Tanaka Y
PLoS One; 2015; 10(2):e0118000. PubMed ID: 25706116
[TBL] [Abstract][Full Text] [Related]
33. Genomic variation-guided management in chronic hepatitis C.
Hsu CS; Kao JH
Expert Rev Gastroenterol Hepatol; 2012 Aug; 6(4):497-506. PubMed ID: 22928901
[TBL] [Abstract][Full Text] [Related]
34. Analysis of IL28B alleles with virologic response patterns and plasma cytokine levels in HIV/HCV-coinfected patients.
Fernández-Rodríguez A; Rallón N; Berenguer J; Jiménez-Sousa MA; Cosín J; Guzmán-Fulgencio M; Restrepo C; Lopez JC; García-Álvarez M; Miralles P; Soriano V; Benito JM; Resino S
AIDS; 2013 Jan; 27(2):163-73. PubMed ID: 23135173
[TBL] [Abstract][Full Text] [Related]
35. Prediction of response to pegylated interferon plus ribavirin in HIV/hepatitis C virus (HCV)-coinfected patients using HCV genotype, IL28B variations, and HCV-RNA load.
Neukam K; Camacho A; Caruz A; Rallón N; Torres-Cornejo A; Rockstroh JK; Macías J; Rivero A; Benito JM; López-Cortés LF; Nattermann J; Gómez-Mateos J; Soriano V; Pineda JA
J Hepatol; 2012 Apr; 56(4):788-94. PubMed ID: 22173157
[TBL] [Abstract][Full Text] [Related]
36. CCL4 is the only predictor for non-responder in GT-1 CHC patients with favorable IL28B genotype when treated with PegIFN/RBV.
Lin CC; Su SH; Jeng WJ; Huang CH; Teng W; Chen WT; Chen YC; Lin CY; Sheen IS
BMC Gastroenterol; 2017 Dec; 17(1):169. PubMed ID: 29284412
[TBL] [Abstract][Full Text] [Related]
37. Amino acid substitution in hepatitis C virus core region and genetic variation near the interleukin 28B gene predict viral response to telaprevir with peginterferon and ribavirin.
Akuta N; Suzuki F; Hirakawa M; Kawamura Y; Yatsuji H; Sezaki H; Suzuki Y; Hosaka T; Kobayashi M; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Chayama K; Nakamura Y; Kumada H
Hepatology; 2010 Aug; 52(2):421-9. PubMed ID: 20648473
[TBL] [Abstract][Full Text] [Related]
38. HCV substitutions and IL28B polymorphisms on outcome of peg-interferon plus ribavirin combination therapy.
Hayes CN; Kobayashi M; Akuta N; Suzuki F; Kumada H; Abe H; Miki D; Imamura M; Ochi H; Kamatani N; Nakamura Y; Chayama K
Gut; 2011 Feb; 60(2):261-7. PubMed ID: 21068134
[TBL] [Abstract][Full Text] [Related]
39. Interleukin-28b CC genotype predicts early treatment response and CT/TT genotypes predicts non-response in patients infected with HCV genotype 3.
Gupta AC; Trehanpati N; Sukriti S; Hissar S; Midha V; Sood A; Sarin SK
J Med Virol; 2014 Apr; 86(4):707-12. PubMed ID: 24415442
[TBL] [Abstract][Full Text] [Related]
40. Review article: genetic factors that modify the outcome of viral hepatitis.
Stättermayer AF; Scherzer T; Beinhardt S; Rutter K; Hofer H; Ferenci P
Aliment Pharmacol Ther; 2014 May; 39(10):1059-70. PubMed ID: 24654629
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
